Australia reschedules naloxone for opioid overdose

Medical Journal of Australia

Volumn 204, Issue 4, 2016, Pages 146-147.e1

  Lenton, Simon R ^a   Dietze, Paul M ^b   Jauncey, Marianne ^c  

^a CURTIN UNIVERSITY   (Australia)

^b BURNET INSTITUTE   (Australia)

^c Sydney Medically Supervised Injecting Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NALOXONE; NON PRESCRIPTION DRUG; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ARTICLE; AUSTRALIA; CLINICAL PRACTICE; DRUG OVERDOSE; EVIDENCE BASED PRACTICE; HUMAN; MORTALITY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PROTOCOL COMPLIANCE; RISK FACTOR; CLASSIFICATION; DRUG CONTROL; HOME CARE;

ANALGESICS, OPIOID; AUSTRALIA; DRUG AND NARCOTIC CONTROL; DRUG OVERDOSE; HOME CARE SERVICES; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; NONPRESCRIPTION DRUGS;

EID: 84960157313     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja15.01181     Document Type: Article

References (13)

1. Therapeutic Goods Administration. Final decisions and reasons for decisions by a delegate of the Secretary to the Department of Health. https://www.tga.gov.au/sites/default/files/finaldecisions-and-reasons-decisions-delegate-medicinessecretary-department-health-november-2015.pdf (accessed Nov 2015).
2. Roxburgh A, Burns L. Accidental drug-induced deaths due to opioids in Australia, 2011. Sydney: National Drug and Alcohol Research Centre, 2015.
3. Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. Inj Epidemiol 2015; 2: 10.
4. Hospira Australia. DBL naloxone hydrochloride injection [product information]. Melbourne: Hospira Australia, 2012. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-PI-00410-3 (accessed Dec 2015).
5. Rudolph SS, Jehu G, Nielsen SL, et al. Prehospital treatment of opioid overdose in Copenhagen-Is it safe to discharge on-scene? Resuscitation 2011; 82: 1410-1413.
6. Wheeler E, Davidson PJ, Stephen Jones T, Irwin KS. Community-based opioid overdose prevention programs providing naloxone — United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 61: 101-105.
7. McAuley A, Best D, Taylor A, et al. From evidence to policy: the Scottish national naloxone programme. Drugs Educ Prev Policy 2012; 19: 309-319.
8. Castillo T. Top 5 reasons why we need over-the-counter naloxone to combat drug overdose. 6 Oct 2014. http://www.huffingtonpost.com/tessie-castillo/top-5-reasons-why-weneed_b_5475235.html (accessed Oct 2015).
9. Wing N. CVS to sell overdose reversal drug without a prescription in 12 more states. http://www.huffingtonpost.com.au/entry/cvs-naloxone-overdose-reversal_5602dba2e4b0fde8b0d0d189?section=australia&adsSiteOverride=au (accessed Sep 2015).
10. Office of the Press Secretary. Fact sheet: Obama administration announces public and private sector efforts to address prescription drug abuse and heroin [press release]. 21 Oct 2015. Washington: The White House. https://www.whitehouse.gov/the-press-office/2015/10/21/fact-sheetobama-administration-announces-public-and-private-sector (accessed Oct 2015).
11. World Health Organization. Community management of opioid overdose. Geneva: WHO, 2014.
12. Olsen A, McDonald D, Lenton S, Dietze P. Independent evaluation of the ‘Implementing Expanded Naloxone Availability in the ACT (I-ENAACT)’ Program, 2011e2014; final report. Melbourne: Centre for Research Into Injecting Drug Use, 2015. http://www.atoda.org.au/wp-content/uploads/Naloxone-Evaluation-Report-FINAL_August-2015_BI.pdf (accessed Oct 2015).
13. Doe-Simkins M, Quinn E, Xuan Z, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health 2014; 14: 297.n